Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.

Borse, Rebekah H; Kachroo, Sumesh; Brown, Chloe; McCann, Eilish; Insinga, Ralph P

Borse, Rebekah H; Kachroo, Sumesh; Brown, Chloe; McCann, Eilish; Insinga, Ralph P.

Afiliação

Borse RH; Merck & Co., Inc., Kenilworth, NJ, USA. rebekah.borse@merck.com.
Kachroo S; Merck & Co., Inc., Kenilworth, NJ, USA.
Brown C; Merck Sharp & Dohme, Hoddesdon, UK.
McCann E; Merck Sharp & Dohme, Hoddesdon, UK.
Insinga RP; Merck & Co., Inc., Kenilworth, NJ, USA.

Rheumatol Ther ; 5(1): 57-73, 2018 Jun.

Article em En | MEDLINE | ID: mdl-29633197

Palavras-chave

Ankylosing spondylitis; Cost-effectiveness; Decision tree; Golimumab; Markov model; Non-radiographic axial spondyloarthritis; Scotland; Tumor necrosis factor inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Rheumatol Ther Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google